Bolt Biotherapeutics, Inc.
BOLTDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
May 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BDC-4182 | Phase 2 | Gastric Cancer Adenocarcinoma Metastatic | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bolt Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Bolt Biotherapeutics, Inc.'s (BOLT) pipeline across Phase 2. Its lead program is BDC-4182 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bolt Biotherapeutics, Inc.'s next FDA catalyst?→
Bolt Biotherapeutics, Inc.'s (BOLT) next tracked catalyst is a Phase 2 expected May 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BOLT biotech catalysts?→
Add BOLT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bolt Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.